Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTPS1 | P17812 | 4/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776413 | 0.89 | CHRNB1 (0.40) | CTPS1XDHPTGS2MKNK1MKNK2 | |
| SCHEMBL3775790 | 0.89 | CHRNB1 (0.40) | MAPTCTPS1XDHSLC22A12EGLN1 | |
| SCHEMBL3774460 | 0.89 | CTSA (0.42) | CTPS1XDHSLC22A12PTGS2BACE1 | |
| SCHEMBL3780251 | 0.87 | XDH (0.46) | XDHSLC22A12EGLN1KCNH2 | |
| SCHEMBL3770617 | 0.86 | CHRNB1 (0.36) | MAPTCTPS1 | |
| SCHEMBL3765822 | 0.85 | XDH (0.40) | XDHSLC22A12EGLN1 | |
| SCHEMBL3780621 | 0.84 | AKT1 (0.33) | CTPS1XDHSLC22A12PTGS2 | |
| SCHEMBL3765737 | 0.84 | KDR (0.40) | — | |
| SCHEMBL3778996 | 0.84 | KDR (0.37) | EGLN1PTGS2 | |
| SCHEMBL3774122 | 0.83 | XDH (0.39) | MAPTXDHSLC22A12EGLN1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | MAPT 3996/4885CTPS1 2954/4885XDH 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.